Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISMA-ESCUDDO Trial
NCT05237947Phase 4Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine, human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, sponsored by National Cancer Institute. Started Mar 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccinehuman papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05237947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237947.